|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
215 897 | 252 318 | 216 827 | 212 162 | - | - |
| Entreprise Value (EV)1 |
239 396 | 275 225 | 259 147 | 250 566 | 234 018 | 245 217 |
| P/E ratio |
10,3x | 23,3x | 13,7x | 17,9x | 15,5x | 14,6x |
| Yield |
3,53% | 3,12% | 3,68% | 3,97% | 4,14% | 4,33% |
| Capitalization / Revenue |
4,11x | 4,70x | 4,19x | 4,32x | 3,99x | 3,98x |
| EV / Revenue |
4,56x | 5,13x | 5,01x | 5,10x | 4,40x | 4,60x |
| EV / EBITDA |
11,3x | 12,6x | 12,3x | 11,2x | 10,0x | 10,3x |
| Price to Book |
3,04x | 3,94x | 3,43x | 3,22x | 3,06x | 2,95x |
| Nbr of stocks (in thousands) |
5 960 707 | 5 780 475 | 5 534 122 | 5 556 880 | - | - |
| Reference price (USD) |
36,2 | 43,7 | 39,2 | 38,2 | 38,2 | 38,2 |
| Last update |
01/30/2018 | 01/29/2019 | 01/28/2020 | 10/22/2020 | 10/22/2020 | 10/22/2020 |
|
1 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
52 546 | 53 647 | 51 750 | 49 149 | 53 126 | 53 339 |
| EBITDA1 |
21 172 | 21 814 | 21 097 | 22 314 | 23 348 | 23 767 |
| Operating profit (EBIT)1 |
19 468 | 20 042 | 19 420 | 17 916 | 19 959 | 20 229 |
| Operating Margin |
37,0% | 37,4% | 37,5% | 36,5% | 37,6% | 37,9% |
| Pre-Tax Profit (EBT)1 |
12 305 | 11 885 | 17 682 | 14 437 | 16 814 | 17 675 |
| Net income1 |
21 308 | 11 153 | 16 273 | 13 239 | 14 105 | 14 520 |
| Net margin |
40,6% | 20,8% | 31,4% | 26,9% | 26,5% | 27,2% |
| EPS2 |
3,52 | 1,87 | 2,87 | 2,13 | 2,46 | 2,62 |
| Dividend per Share2 |
1,28 | 1,36 | 1,44 | 1,52 | 1,58 | 1,65 |
| Last update |
01/30/2018 | 01/29/2019 | 01/28/2020 | 10/22/2020 | 10/22/2020 | 10/22/2020 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
23 499 | 22 907 | 42 320 | 38 405 | 21 856 | 33 055 |
| Net Cash position1 |
- | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
1,11x | 1,05x | 2,01x | 1,72x | 0,94x | 1,39x |
| Free Cash Flow1 |
14 514 | 13 785 | 10 412 | 15 776 | 16 159 | 16 940 |
| ROE (Net Profit / Equities) |
24,6% | 16,6% | 25,7% | 22,7% | 25,3% | 24,9% |
| Shareholders' equity1 |
86 671 | 67 357 | 63 275 | 58 423 | 55 859 | 58 253 |
| ROA (Net Profit / Asset) |
9,37% | 6,73% | 9,96% | 7,30% | 8,50% | 9,00% |
| Assets1 |
227 460 | 165 609 | 163 456 | 181 363 | 165 935 | 161 328 |
| Book Value Per Share2 |
11,9 | 11,1 | 11,4 | 11,9 | 12,5 | 13,0 |
| Cash Flow per Share2 |
2,72 | 2,65 | 2,22 | 1,96 | 2,91 | 3,07 |
| Capex1 |
1 956 | 2 042 | 2 176 | 2 030 | 2 110 | 2 148 |
| Capex / Sales |
3,72% | 3,81% | 4,20% | 4,13% | 3,97% | 4,03% |
| Last update |
01/30/2018 | 01/29/2019 | 01/28/2020 | 10/22/2020 | 10/22/2020 | 10/22/2020 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2020 S&P Global Market Intelligence
|
|
|
Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources |
Capitalization (USD) 212 161 671 031 Net sales (USD) 51 750 000 000 Number of employees 88 300 Sales / Employee (USD) 586 070 Free-Float capitalization (USD) 125 400 262 181 Avg. Exchange 20 sessions (USD) 876 488 952 Average Daily Capital Traded 0,41%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
